Trial Profile
Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamid and Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Antithymocyte globulin; Busulfan; Cyclophosphamide; Methotrexate; Mycophenolate mofetil; Tacrolimus
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 14 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Jan 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 10 Feb 2010 Planned end date changed from Dec 2010 to Dec 2011 as reported by ClinicalTrials.gov.